Chengdu Company Profile
What is the competitive landscape for CHENGDU
CHENGDU has four approved drugs.
Drugs and US Patents for Chengdu
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chengdu Shuode | METHYLENE BLUE | methylene blue | SOLUTION;INTRAVENOUS | 219550-001 | Dec 23, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chengdu | TACROLIMUS | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 215012-003 | Jan 25, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-001 | Nov 15, 2023 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

